Xenon Pharmaceuticals

Xenon Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It develops therapeutics to improve the lives of patients with neurological disorders, including rare central nervous system (CNS) conditions. The company's products include XEN496, XEN1101, XEN901 and XEN007. Xenon Pharmaceuticals was founded by Simon Neil Pimstone, Johannes J. P. Kastelein and Michael R. Hayden on November 5, 1996 and is headquartered in Burnaby, Canada.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Xenon Pharmaceuticals excels in epilepsy treatment with strong IP strategy

Xenon Pharmaceuticals demonstrated strong performance and promising efficacy data for XEN1101 in epilepsy treatment, supported by a robust IP strategy and CNS penetration.
While facing challenges in patient enrollment and rising expenses, the company is exploring new therapeutic areas and potential milestone payments through partnerships.
Opportunities lie in expanding XEN1101's market reach, establishing a leadership position in epilepsy treatment, and navigating uncertainties in pediatric indications and generic competition.

Xenon Pharmaceuticals advances epilepsy program amid financial stability and challenges

Xenon Pharmaceuticals showcased progress in their epilepsy program and financial stability, while addressing challenges in enrollment dynamics and competitive pressures.
The company's focus on managing R&D expenses and upcoming milestones reflects a strategic approach to advancing their clinical programs.
Opportunities in the epilepsy market and ongoing formulation development for pediatric patients position Xenon for potential growth and innovation.

Xenon Pharmaceuticals excels in trials and finances, eyes global expansion

Xenon Pharmaceuticals showcases strong performance in key trials and financial stability, supported by positive market reception and strategic leadership additions.
While facing challenges in trial completion and enrollment trends, the company has opportunities to expand market reach, innovate in treatment approaches, and explore global partnerships.
Overall, Xenon's focus on advancing novel therapies for neurological disorders positions it well for future growth and success in the competitive pharmaceutical landscape.

Xenon Pharmaceuticals advances epilepsy and MDD treatments, poised for growth

Xenon Pharmaceuticals showcased strong performance in advancing XEN1101 for epilepsy and MDD treatments, backed by extensive data and strategic partnerships.
While facing challenges in enrollment timelines and technical complexities, the company is well-positioned financially and strategically for future growth.
Opportunities abound in addressing unmet needs, expanding drug applications, and advancing new molecules into clinical development.
Overall, Xenon Pharmaceuticals' Q3 earnings call highlighted a promising outlook for drug development and market positioning.

Xenon Pharmaceuticals excels in Q4, poised for growth in epilepsy and MDD

Xenon Pharmaceuticals showcased strong financials, program advancements, and market insights in Q4 2023, positioning the company well for future growth.
The company's focus on safety, tolerability, and efficacy in MDD treatment, along with leveraging learnings across programs, demonstrates strategic foresight.
While facing challenges in R&D spend allocation and regulatory discussions, Xenon can capitalize on opportunities for operational efficiency and market expansion.
Investor interest in Xenon's pipeline and the potential of its programs in epilepsy and MDD highlight a promising trajectory for the company.

Xenon Pharmaceuticals reports strong Q1 performance and addresses market needs

Xenon Pharmaceuticals is well-positioned with a strong financial base and promising pipeline.
The company faces challenges in conducting well-powered MDD trials and addressing market needs.
Opportunities lie in the substantial unmet need in the major depressive market and azetukalner's potential benefits.
Strategic planning and FDA alignment support Xenon's progress in key therapeutic areas.

Xenon Pharmaceuticals excels in Q3, poised for groundbreaking treatments

Xenon Pharmaceuticals demonstrated strong financial performance and progress in developing azetukalner for epilepsy and major depressive disorder.
Confidence in the lead product's potential for groundbreaking treatments was evident, supported by ongoing outreach efforts and future milestones.
While facing challenges in addressing complex analyst inquiries and navigating regulatory requirements, Xenon Pharmaceuticals is well-positioned to capitalize on opportunities for growth and innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BURNABY, British Columbia, Jan. 12, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that its collaboration to develop treatments for epilepsy with Neurocrine Biosciences, Inc. (Nasdaq: NBIX) achieved a regulatory milestone, which has triggered an aggregate payment of $15.0 million to Xenon. The U.S. Food and Drug Administration (FDA) accepted Neurocrine's protocol amendment that expands the study population to include subjects aged between 2 and 11 years in the ongoing Phase 2 randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, tolerability, and pharmacokinetics of NBI-921352 in pediatric patients with SCN8A developmental and epileptic encephalopathy (SCN8A-DEE).

Xenon Pharmaceuticals Announces Collaboration with Neurocrine Biosciences Achieves $15.0 Million Regulatory Milestone

BURNABY, British Columbia, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today outlined its key milestones for 2022.

Xenon Pharmaceuticals Outlines Key Milestone Opportunities for 2022

Chinook Therapeutics

For most issues in the biotech sector, it was a rough 2021, especially when compared to the gains in the S&P 500 index, Wedbush's Laura Chico said Wednesday on "PreMarket Prep Plus." Chico, the senior vice president of biotech equity research at the analyst firm, said she attributes the underperformance to a few factors.

Wednesdays With Wedbush: Analyst Laura Chico On The State Of Biotech

Xenon Pharmaceuticals Inc (NASDAQ: XENE) announced additional positive data from new sub-analyses of Phase 2b X-TOLE trial of XEN1101 in adult patients with focal epilepsy. The Data will be presented at the Annual Meeting of the American Epilepsy Society.

Xenon Stock Jumps On New Encouraging Data From Epilepsy Treatment

Topline Data Showed All Primary and Secondary Seizure Reduction Endpoints Statistically Significant Across All Dose Groups, with p-value of

Xenon Pharmaceuticals Presents Additional Positive Data from Phase 2b ‘X-TOLE' Clinical Trial at the Annual Meeting of the American Epilepsy Society (AES 2021)

BURNABY, British Columbia, Dec. 03, 2021 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that it will provide updates on its proprietary, neurology programs at the Annual Meeting of the American Epilepsy Society (AES 2021).

Xenon Pharmaceuticals Provides Updates on Proprietary Neurology Pipeline Programs at the Annual Meeting of the American Epilepsy Society (AES 2021)

Xenon Pharmaceuticals' (XENE) CEO Ian Mortimer on Q3 2021 Results - Earnings Call Transcript

Xenon Pharmaceuticals (XENE) delivered earnings and revenue surprises of 18.18% and 4.69%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Xenon Pharmaceuticals (XENE) Reports Q3 Loss, Tops Revenue Estimates

XEN1101 X-TOLE Presentations Scheduled at AES 2021 with Planning Underway for Phase 3 Initiation in 2022

Xenon Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update

BURNABY, British Columbia, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced it will report its third quarter 2021 financial and operating results after the close of U.S. financial markets on Wednesday, November 10, 2021.

Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Third Quarter 2021 Financial Results and Provide Corporate Update

XENE stock is a valuable stock market lesson about separating great expectations for stocks from the company's true fundamentals. The post Xenon Pharmaceuticals Has a Great Story But Too High a Price appeared first on InvestorPlace.

Xenon Pharmaceuticals Has a Great Story But Too High a Price

Xenon Pharmaceuticals (XENE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Xenon Pharmaceuticals (XENE) Q3 Earnings Expected to Decline

Xenon just delivered strong clinical trial results and leveraged that into a strong fundraising effort. That has XENE stock in a good place going forward.

Xenon: Heading Toward Phase III With Strong Momentum

XENE stock deserved to move higher but was stuck for months -- until a game-changing epilepsy treatment put Xenon in the spotlight again. The post New Clinical Results Make Xenon Pharmaceuticals' Stock Worthy Again appeared first on InvestorPlace.

New Clinical Results Make Xenon Pharmaceuticals' Stock Worthy Again

Shares of Xenon Pharmaceuticals Inc . (NASDAQ: XENE) traded at a new 52-week high today of $34.80.

Shares of Xenon Pharmaceuticals Inc. Have Risen Above Previous 52-Week High

Alnylam Pharmaceuticals

Palo Alto Networks

These top performers have what it takes to keep providing outsized gains for patient investors.

3 Growth Stocks Near 52-Week Highs to Buy Anyway

BURNABY, British Columbia, Oct. 08, 2021 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today announced the closing of its previously announced underwritten public offering of 10,000,000 common shares, which includes 1,525,423 shares sold upon the full exercise of the underwriters' option to purchase additional shares, and pre-funded warrants to purchase 1,694,915 common shares. The common shares were offered at a public offering price of $29.50 per common share and the pre-funded warrants were offered at a price of $29.4999 per pre-funded warrant, with each pre-funded warrant having an exercise price of $0.0001. The aggregate gross proceeds to Xenon from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Xenon, were approximately $345.0 million.

Xenon Pharmaceuticals Announces Closing of $345 Million Public Offering Including Full Exercise of the Underwriters' Option to Purchase Additional Shares

The stock price of Xenon Pharmaceuticals Inc (NASDAQ: XENE) increased by over 6% today. This is why it happened.

XENE Stock: Why It Increased Today

Xenon Pharmaceuticals Inc (NASDAQ: XENE) priced its underwritten public offering of 8.5 million shares and pre-funded warrants to purchase up to 1.7 million shares. The common share offer price of $29.50 represents a marginal discount of 1.6% over the last close price of $29.99 on Tuesday.

Xenon Pharmaceuticals Raises $300M Via Equity

BURNABY, British Columbia, Oct. 05, 2021 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today announced the pricing of its underwritten public offering of 8,474,577 common shares and, in lieu of common shares to certain investors, pre-funded warrants to purchase up to 1,694,915 common shares pursuant to its existing shelf registration statement. The common shares are being offered at a public offering price of $29.50 per common share and the pre-funded warrants are being offered at a price of $29.4999 per pre-funded warrant. The gross proceeds to Xenon from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Xenon, are expected to be approximately $300.0 million. In addition, Xenon has granted to the underwriters of the offering an option for a period of 30 days to purchase up to an additional 1,525,423 common shares at the public offering price, less the underwriting discounts and commissions. The offering is expected to close on or about October 8, 2021, subject to customary closing conditions.

Xenon Pharmaceuticals Announces Pricing of $300.0 Million Public Offering

The stock price of Xenon Pharmaceuticals Inc (NASDAQ: XENE) increased by over 100% this week. This is why it happened.

XENE Stock: Why It Substantially Increased This Week

Despite the big run-up yesterday, there could be enough fuel to push this biotech stock even higher.

Is Xenon Pharmaceuticals a Good Stock to Buy Now?

Xenon Pharmaceuticals Inc (NASDAQ:XENE) stock is soaring today, up 90.8% to trade at $29.76 at last glance, after the company met its main goal in a phase 2 study of its epilepsy treatment XEN1101.

Pharma Stock Soars to Record Highs After Epilepsy Drug Study Results

Here's why investors in clinical-stage biotech stock Xenon Pharmaceuticals are cheering today as XENE stock runs wild. The post XENE Stock: The Huge FDA News Sending Xenon Pharmaceuticals to the Moon appeared first on InvestorPlace.

XENE Stock: The Huge FDA News Sending Xenon Pharmaceuticals to the Moon

Xenon Pharmaceuticals Inc (NASDAQ: XENE) has reported topline results from the Phase 2b X-TOLE trial evaluating XEN1101 as an adjunctive treatment in adult patients with focal epilepsy. The trial met its primary efficacy endpoint with XEN1101, demonstrating a statistically significant and dose-dependent reduction from baseline in monthly focal seizure frequency compared to placebo.

News for Xenon Pharmaceuticals Stock (XENE)